Abstract
The combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue was evaluated in the treatment of relapsed leukemia refractory to normal-dose chemotherapy. Cyclophosphamide was given at a total dose of 4.5 g/m2, BCNU at a dose of 300 mg/m2, and VP-16-213 at a dose of 600 mg/m2. Seven high-dose treatments followed by marrow rescue were administered to six patients. Two patients achieved complete remissions, three had partial remissions, and one achieved a minimal response. The toxicity of this regimen was moderate.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acute Disease
-
Adult
-
Bone Marrow Transplantation*
-
Carmustine / administration & dosage*
-
Cyclophosphamide / administration & dosage*
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Humans
-
Leukemia / therapy*
-
Leukemia, Lymphoid / therapy
-
Leukemia, Myeloid, Acute / therapy
-
Male
-
Pilot Projects
-
Podophyllotoxin / analogs & derivatives*
-
Recurrence
-
Transplantation, Autologous
Substances
-
Etoposide
-
Cyclophosphamide
-
Podophyllotoxin
-
Carmustine